Alan Mitchell
Impact in
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- Oncology top 1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Polyomavirus and related diseases
Papers in
- Hematology 16
- Multiple Myeloma Research and Treatments 16
-
- Lung Cancer Diagnosis and Treatment 8
- Occupational and environmental lung diseases 6
- Lung Cancer Treatments and Mutations 4
- Co-authors
- John Crowley (12 shared papers)Bart Barlogie (14 shared papers)Frits van Rhee (10 shared papers)Ramón Rami–Porta (2 shared papers)Gareth John Morgan (8 shared papers)Wilfried Ernst Erich Eberhardt (1 shared paper)Andrew T. Turrisi (1 shared paper)Peter G. Goldstraw (1 shared paper)
- Journals
- Journal of Thoracic Oncology (15 papers)Blood (13 papers)The Lancet (3 papers)Clinical Cancer Research (2 papers)The Annals of Thoracic Surgery (1 paper)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Alan Mitchell
38 papers receiving 8.8k citations
Alan Mitchell's Hit Papers
Peers
Comparison fields: 5 of 121
- Pulmonary and Respiratory Medicine 4.3k
- Oncology 2.7k
- Microbiology 40
- Hematology 479
- Radiology, Nuclear Medicine and Imaging 840
Countries citing papers authored by Alan Mitchell
This map shows the geographic impact of Alan Mitchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Mitchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Mitchell more than expected).
Fields of papers citing papers by Alan Mitchell
This network shows the impact of papers produced by Alan Mitchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Mitchell. The network helps show where Alan Mitchell may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Mitchell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer Hit paper breakdown → | 2016 | 3512 |
| 2 | PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma Hit paper breakdown → | 2016 | 1030 |
| 3 | The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer Hit paper breakdown → | 2016 | 594 |
| 4 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 5 | The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer Hit paper breakdown → | 2017 | 383 |
| 6 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 7 | 2015 | 332 | |
| 8 | 2015 | 311 | |
| 9 | 2016 | 217 | |
| 10 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 11 | 2014 | 201 | |
| 12 | 2016 | 190 | |
| 13 | 2013 | 171 | |
| 14 | 2016 | 150 | |
| 15 | 2016 | 144 | |
| 16 | 2016 | 143 | |
| 17 | 2016 | 137 | |
| 18 | 2016 | 102 | |
| 19 | 2016 | 99 | |
| 20 | 2016 | 63 |
About Alan Mitchell
Alan Mitchell is a scholar working on Hematology, Pulmonary and Respiratory Medicine, Oncology, Statistics and Probability and Molecular Biology, having authored 38 papers that have together received 9.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (10 papers), Lung Cancer Diagnosis and Treatment (8 papers), Occupational and environmental lung diseases (6 papers), Peptidase Inhibition and Analysis (5 papers), Lung Cancer Treatments and Mutations (4 papers), Statistical Methods in Clinical Trials (3 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.3k citations), Oncology (2.7k citations), Microbiology (40 citations), Hematology (479 citations) and Radiology, Nuclear Medicine and Imaging (840 citations). Alan Mitchell has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include John Crowley, Bart Barlogie, Frits van Rhee, Ramón Rami–Porta, Gareth John Morgan, Wilfried Ernst Erich Eberhardt, Andrew T. Turrisi, Peter G. Goldstraw, Haruhiko Kondo and Young Tae Kim. Their work appears in journals such as Journal of Thoracic Oncology, Blood, The Lancet, Clinical Cancer Research and The Annals of Thoracic Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.